Lytenava is indicated in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD).
JOBEVNE — BIOCON BIOLOGICS INC, approved 2025-04-09 (BLA761175).
93,213 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.